Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.6 (thromboplastin)
 13,278 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Effects of a new antiovulatory steroid (Ro 6-5403) on gonadotropins, prolactin, and blood coagulation were studied in 8 normally menstruating women who had previously undergone tubal ligation. Blood was obtained at 1-5 day intervals during 3 cycles: 1 cycle before treatment, 1 cycle during treatment of 2 mg Ro 6-5403 orally twice daily from cycle Day 5 through 24 and 1 cycle following treatment. Low plasma levels of progesterone and ihibition of release of luteinizing hormone and follicle stimulating hormone indicated suppression of ovulation during treatment. Prolactin levels were significantly elevated (p less than .001) during treatment. Fibrinogen concentration was significantly elevated (p less than .01) and the mean number of platelets was increased. Thromboelastography showed significantly reduced values for k-time (p less than .05) and significantly increased values for maximal amplitude (p less than .05). Thrombin time was decreased and partial thromboplastin time was significantly decreased (p less than .01) during treatment. All parameters returned to pretreatment values except thrombin time where the decrease continued to a significant difference (p less than .01). The side effects subsided after the initial day of treatment. Liver and kidney parameters remained within the physiological range. "Hypercoagulability" and elevated prolactin levels were interpreted as related to the estrogenlike activity of Ro 6-5403.
 ...
PMID:Effects of a new antiovulatory steroid on gonadotropins, prolactin and blood coagulation. 117 71